A phase II study of addition of pracinostat to a hypomethylating agent in patients with myelodysplastic syndromes who have not responded to previous hypomethylating agent therapy
Pharmacology, Toxicology and Pharmaceutical Science
1
6%
Biochemistry, Genetics and Molecular Biology
1
6%
Business, Management and Accounting
1
6%
Chemistry
1
6%
Other
0
0%
Unknown
5
31%
Attention Score in Context
Attention Score in Context
This research output has an Altmetric Attention Score of 9. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 15 November 2019.
All research outputs
#4,398,408
of 26,877,159 outputs
Outputs from British Journal of Haematology
#1,424
of 8,450 outputs
Outputs of similar age
#75,638
of 353,496 outputs
Outputs of similar age from British Journal of Haematology
#23
of 100 outputs
Altmetric has tracked 26,877,159 research outputs across all sources so far. Compared to these this one has done well and is in the 83rd percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 8,450 research outputs from this source. They typically receive a little more attention than average, with a mean Attention Score of 7.2. This one has done well, scoring higher than 83% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 353,496 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 78% of its contemporaries.
We're also able to compare this research output to 100 others from the same source and published within six weeks on either side of this one. This one has done well, scoring higher than 77% of its contemporaries.
